Celebrating the 35th Anniversary of the Terry Fox Marathon of Hope in the city where Terry Fox began his epic run across Canada.

Célébration du 35e anniversaire du Marathon de l’espoir de Terry Fox dans la ville où Terry Fox a débuté sa course épique à travers le Canada.
## CONTENTS

<table>
<thead>
<tr>
<th>ITEM</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plenaries</td>
<td></td>
</tr>
<tr>
<td><strong>Thursday, May 7</strong></td>
<td></td>
</tr>
<tr>
<td>Plenary 1</td>
<td>3 – 4</td>
</tr>
<tr>
<td>Plenary 2</td>
<td>5 – 6</td>
</tr>
<tr>
<td><strong>Friday, May 8</strong></td>
<td></td>
</tr>
<tr>
<td>Plenary 3</td>
<td>7 – 9</td>
</tr>
<tr>
<td><strong>Saturday, May 9</strong></td>
<td></td>
</tr>
<tr>
<td>Plenary 4</td>
<td>10 – 11</td>
</tr>
<tr>
<td>Workshops</td>
<td></td>
</tr>
<tr>
<td><strong>Friday, May 8</strong></td>
<td></td>
</tr>
<tr>
<td>Workshop 1</td>
<td>12</td>
</tr>
<tr>
<td>Workshop 2</td>
<td>12 – 13</td>
</tr>
<tr>
<td>Workshop 3</td>
<td>13</td>
</tr>
<tr>
<td>Workshop 4</td>
<td>14</td>
</tr>
<tr>
<td>Workshop 5</td>
<td>14 – 15</td>
</tr>
<tr>
<td>Workshop 6</td>
<td>15</td>
</tr>
<tr>
<td>Presentations</td>
<td></td>
</tr>
<tr>
<td>Trainee Oral Presentations</td>
<td>16</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SPEAKERS, WORKSHOP</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CO-DISCUSSANTS &amp; CHAIRS</strong></td>
<td></td>
</tr>
<tr>
<td>(ALPHA LISTING)</td>
<td></td>
</tr>
<tr>
<td>Aparicio, Sam</td>
<td>8</td>
</tr>
<tr>
<td>Bell, John</td>
<td>14</td>
</tr>
<tr>
<td>Boutros, Paul</td>
<td>3</td>
</tr>
<tr>
<td>Bray, Judith</td>
<td>12</td>
</tr>
<tr>
<td>Bristow, Robert</td>
<td>3</td>
</tr>
<tr>
<td>Dancey, Janet</td>
<td>15</td>
</tr>
<tr>
<td>Dorward, Ann</td>
<td>6</td>
</tr>
<tr>
<td>Drover, Sheila</td>
<td>5</td>
</tr>
<tr>
<td>Fields, Tony</td>
<td>10</td>
</tr>
<tr>
<td>Gleave, Martin</td>
<td>3</td>
</tr>
<tr>
<td>Hirasawa, Ken</td>
<td>6</td>
</tr>
<tr>
<td>Huntsman, David</td>
<td>8</td>
</tr>
<tr>
<td>Johnston, Gerry</td>
<td>7 &amp; 11</td>
</tr>
<tr>
<td>Johnston, Michael</td>
<td>10</td>
</tr>
<tr>
<td>Lam, Stephen</td>
<td>13</td>
</tr>
<tr>
<td>Larijani, Mani</td>
<td>5 &amp; 6</td>
</tr>
<tr>
<td>Ling, Victor</td>
<td>10</td>
</tr>
<tr>
<td>Malkin, David</td>
<td>8</td>
</tr>
<tr>
<td>Marra, Marco</td>
<td>9</td>
</tr>
<tr>
<td>Mes-Masson, Anne-Marie</td>
<td>16</td>
</tr>
<tr>
<td>Nelson, Brad</td>
<td>12</td>
</tr>
<tr>
<td>O’Brien, Catherine</td>
<td>11 &amp; 14</td>
</tr>
<tr>
<td>Ohashi, Pam</td>
<td>13</td>
</tr>
<tr>
<td>Parfrey, Pat</td>
<td>5</td>
</tr>
<tr>
<td>Park, Morag</td>
<td>10</td>
</tr>
<tr>
<td>Parker, Louise</td>
<td>13</td>
</tr>
<tr>
<td>Parkinson, David</td>
<td>12</td>
</tr>
<tr>
<td>Rodier, Francis</td>
<td>14</td>
</tr>
<tr>
<td>Saad, Fred</td>
<td>4</td>
</tr>
<tr>
<td>Siu, Lillian</td>
<td>15</td>
</tr>
<tr>
<td>Sutcliffe, Simon</td>
<td>7</td>
</tr>
<tr>
<td>Wang, Peter</td>
<td>5</td>
</tr>
<tr>
<td>Williams, Christine</td>
<td>11</td>
</tr>
<tr>
<td>Wouters, Bradley</td>
<td>14</td>
</tr>
</tbody>
</table>
Chair

Paul Boutros

Dr. Paul Boutros is a principal investigator in informatics and biocomputing at the Ontario Institute for Cancer Research (OICR) and an assistant professor in the departments of pharmacology and toxicology, and medical biophysics at the University of Toronto. Dr. Boutros completed his undergraduate education (chemistry) at the University of Waterloo, during which time he completed a work term at Michigan State University developing computer models of how cells respond to drugs and toxins. He was awarded his PhD in 2008 for his development of novel biomarkers for predicting cancer severity. Dr. Boutros’ research focuses on personalizing therapy for prostate cancer by developing novel statistical methodologies. He leads the bioinformatics analysis of the sequencing of 500 prostate cancers as part of the Canadian Prostate Cancer Genome Network (CPC-GENE), and is using these data to develop biomarkers for intermediate-risk prostate cancer. He is a Terry Fox New Investigator award recipient.

Speakers

Robert Bristow

Dr. Robert Bristow is a clinician-scientist at Princess Margaret Cancer Centre where he is treats genitourinary cancers and a professor within the departments of radiation oncology and medical biophysics at the University of Toronto. His primary research interests are in tumour hypoxia, genome instability and prostate cancer genomics in the context of personalized cancer medicine. He is the lead PI for the Canadian component of the ICGC whole genome prostate cancer sequencing project (CPC-GENE) and is head, Campbell Family Research Institute-PMH Prostate Cancer Research Program. He also serves on the scientific advisory board/committee for Prostate Cancer Canada (co-chair), the Prostate Cancer Foundation (USA), the Advisory Council for Research (ACOR) of Canadian Cancer Society Research Institute, the Movember Global Strategic Committee and Action Plan (GAP) and the Cancer Research Society. Dr. Bristow is editor of the 5th Edition Basic Science of Oncology and has over 200 published papers and book chapters. Dr. Bristow has won a number of awards including the Virginia Logan Lectureship (Thomas Jefferson University), the Picchione Scholar Award (Pathology-Dalhousie University), Vivian Sakyly Visiting Professor (Oncology-McGill University) and the John F. Ferguson Prostate Cancer Hero Award (Prostate Cancer Canada).

Martin Gleave

Dr. Martin Gleave is a clinician-scientist and urologic surgeon. He is a distinguished professor and head of the department of urologic sciences at the University of British Columbia (UBC), director of the Vancouver Prostate Center, and a British Columbia leadership chair. He has published over 400 papers with 22,000 citations, has an H-Index of 84, an i10 index of 305, and attracted >$80M in research funding. His research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on adaptive survival responses that drive acquired treatment resistance, and designing rational combination co-targeting strategies to create conditional lethality and improve cancer control. He patented several anti-cancer drugs and, in 2001, founded OncoGenex Pharmaceuticals to develop OGX-011, an inhibitor of the cell survival gene clusterin, which potentiates anti-cancer therapies in many cancer models. He also discovered OGX-427, another drug targeting Hsp27 that has demonstrated single agent activity in Phase II studies of castrate resistant prostate cancer and bladder cancer. Dr. Gleave has received the Aubrey Tingle Prize from the Michael Smith Foundation for Health Research; the NCIC William Rawls Award for contributions to cancer control in Canada; the Barringer Medal (American Association of GU Surgeons); and the Eugene Fuller Award (American Urological Association).
Speakers (continued)

Fred Saad

Dr. Fred Saad is professor and chief of urology and director of G-U Oncology at the University of Montreal Hospital Centers (CHUM). He holds the U of M Endowed Chair in Prostate Cancer Research and is director of the molecular oncology research lab in prostate cancer. He is also director of clinical cancer research at the CHUM research center (CRCHUM). Dr Saad is lead investigator of the Canadian Prostate Cancer Biomarker Network (CPCBN) funded by the Terry Fox Research Institute and is a principal investigator with the Movember bio-marker initiatives in prostate cancer. Between 2007 and 2013 he chaired the National Cancer Institute of Canada G-U Group and the Canadian Urologic Oncology Group. He has published over 300 articles in several prestigious journals such as The New England Journal of Medicine, Lancet, JCO and JNCI. He sits on seven editorial boards and is a reviewer for over 30 scientific journals. He is an author on over 800 scientific abstracts, five books and over 30 book chapters. Dr. Saad’s research interests include molecular prognostic markers, mechanisms of progression and new therapeutics in prostate cancer. He has over 40 clinical and basic research projects ongoing. To date, he has received over $20 million in research grants.
PLENARY 2: Thursday, May 7

Co-chairs

Sheila Drover
Dr. Sheila Drover is an associate professor in the division of biomedical sciences at Memorial University of Newfoundland, an HLA consultant with Eastern Health Corporation and a senior scientist at the Beatrice Hunter Cancer Research Institute. She received her PhD in immunology at Memorial University and did postdoctoral studies on HLA-DR4 epitopes and rheumatoid arthritis with Dr. Gerry Nepom at the Benaroya Research Institute in Seattle, Washington. Her research evolved from studies on the role of HLA in autoimmune diseases to its role in cancer immunity. Her current research, funded by the Canadian Breast Cancer Foundation, is focused on hormonal and growth factor regulation of antigen presentation pathways in breast carcinoma.

Mani Larijani
Dr. Mani Larijani is an associate professor of immunology and infectious diseases in the department of biomedical sciences, Memorial University of Newfoundland, where he took up his position as a faculty member in the summer of 2009. His research interests lie in understanding genome-mutating enzymes: their mechanisms, regulation in normal vs. cancer cells, and facets through which they contribute to immunity, cancer and evolution of viruses. Mani completed his PhD jointly at the department of immunology, University of Toronto, and the department of genetics, Harvard. Peer-reviewed awards and recognitions in the last five years include: The New Investigator Award from the Canadian Society for Immunology, CIHR New Investigator Award, the President’s Award for Outstanding Research at Memorial University, the Terra Nova Young Innovator Award at Memorial University, the Wallace Ingram Award for Faculty in Medicine at Memorial University, and early tenure and promotion to the rank of associate professor. Dr. Larijani’s research is currently supported by the CIHR and the Canadian Cancer Society. He is an invited peer reviewer panel member for CIHR, NIH, CCS and Canadian Breast Cancer Foundation, amongst other agencies. He is also a BHCRI senior scientist and co-chair of the BHCRI studentship funding panel.

Speakers

Pat Parfrey
Dr. Pat Parfrey is a Distinguished University Professor at Memorial University, chief scientific officer for the Translational and Personalized Medicine Initiative, a staff nephrologist and clinical epidemiologist. He was named an Officer to the Order of Canada in 2004, and fellow of the Royal Society of Canada in 2009. He and his research teams have produced quality research in three major areas: clinical epidemiology in nephrology, clinical and genetic epidemiology of inherited diseases, and health care delivery research. In nephrology, a major theme has been the identification of risk factors and management of cardiac disease in chronic kidney disease. In inherited diseases, the focus has been on the clinical and genetic epidemiology of renal cystic diseases, sudden cardiac death, and colorectal cancer. In health care delivery, the objective has been to get the right intervention to the right person at the right time, using measures of increased risk, whether these measures are clinical prediction models or genomic tests.

Peter Wang
Dr. Wang is a tenured professor of epidemiology in the Faculty of Medicine, Memorial University of Newfoundland (MIUN) and a senior scientist at BHCRI. Dr. Wang graduated from Tianjin Medical University, China and received his PhD in epidemiology from the Dalla Lana School of Public Health, University of Toronto. While Dr. Wang has very broad research interests, his main research has been in cancer epidemiology, focusing on lifestyle and its impact on colorectal cancer. His research has been supported by both national and provincial funding agencies including CIHR, TFRI, and the Newfoundland and Labrador Centre for Applied Health Research. Among many recognitions, Dr. Wang received the CIHR Fellowship Award, Distinguished Visiting Professor Award from Tianjin Government, and Science and Chinese National Technology Achievement Award and Fellow of American Academy of Health Behavior. He has been a lead investigator or a co-investigator for more than 30 research grants that have been supported by various provincial, national and international funding agencies. He has published more than 80 articles in peer-reviewed scientific journals. In the past 10 years, Dr. Wang’s main research focus has been in epidemiology of colorectal cancer and his research in this area has been well recognized internationally.
Speakers (continued)

Ann Dorward
Dr. Ann Dorward completed her undergraduate and graduate degrees at McMaster University. She pursued post-doctoral training at The Jackson Laboratory (Bar Harbor, Maine) in the field of mouse genetics, staying on as a research scientist with projects related to ovarian tumour susceptibility, malignant progression of hormone-dependent tumours and experimental therapeutics for cancer. Now on faculty at Memorial University of Newfoundland, she continues to work with mouse models for the purpose of investigating the causes and outcomes of human genetic disease, toxicological modelling and experimental photomedicine for cancer. Dr. Dorward has received funding as a primary applicant or co-applicant from the NIH, CIHR, CRC, CFI and the CCSRI. In addition to her research program, Dr. Dorward is very involved in graduate mentorship and volunteer work for foundations and charities.

Ken Hirasawa
Dr. Hirasawa was born in Tokyo, Japan and obtained his PhD at the University of Tokyo in veterinary science in 1996. He then took up a postdoctoral fellowship in department of microbiology and infectious disease at the University of Calgary. He worked in the laboratory of Dr. Patrick Lee on the human reovirus, called an oncolytic virus, which replicates and kills cancer cells with an activated Ras pathway, but not normal cells. In 2003, he moved to St. John’s to take a position as an assistant professor with the division of biomedical sciences, Faculty of Medicine, Memorial University of Newfoundland. His current research focuses on downregulation of interferon regulatory factor 1 (IRF-1) in cancer cells which promotes cancer cell sensitivity to viral oncolysis as well as tumour development. His research is currently supported by several granting agencies such as CIHR, NSERC, CCSRI and CBCF. Dr. Hirasawa is currently an associate professor in the immunology and infectious disease research group. He is well-adapted to Newfoundland and is the president of Newfoundland Japanese society.

Mani Larijani
See page 5.
**Co-chairs**

**Simon Sutcliffe**
A graduate of St. Bartholomew’s Hospital, London, England in 1970, Dr. Sutcliffe’s training encompassed internal medicine, scientific research, medical and radiation oncology in the UK, South Africa, US and Canada. Staff appointments have been held at St. Bartholomew’s Hospital, Princess Margaret Hospital/Ontario Cancer Institute and the BC Cancer Agency. He has been president and CEO of the Princess Margaret Hospital/Ontario Cancer Institute (1994 –1996) and the BC Cancer Agency (2000 – 2009). He chairs the Board of the Institute for Health Systems Transformation and Sustainability; is president of the International Cancer Control Congress Association, the International Network for Cancer Treatment and Research–Canada Branch (Two Worlds Cancer Collaboration); is a senior advisor to the Terry Fox Research Institute and is chief medical officer for QuBiologics Inc. and Omnitura Inc. He is a past chair of the board of the Canadian Partnership Against Cancer (2009 – 2012), the Michael Smith Foundation for Health Research (MSFHR, 2000 – 2007) and has served on the boards of CPAC, MSFHR, and Genome BC. He is an adjunct clinical professor at the University of British Columbia and an associate scientist with the Michael Smith Genome Sciences Centre at the BC Cancer Agency. Dr. Sutcliffe was awarded the Queen Elizabeth 50th Jubilee Gold Medal in 2003, and the Terry Fox Award of the BC Medical Association in 2009 for his lifetime services to cancer control.

**Gerry Johnston**
Dr. Gerry Johnston is currently associate dean (research) in the Faculty of Medicine and professor in the department of microbiology and immunology at Dalhousie University (Halifax, Nova Scotia). With Dr. Richard Singer (department of biochemistry and molecular biology), the Johnston/Singer lab utilizes the genetic and molecular facility of the budding yeast, *saccharomyces cerevisiae*, to explore fundamental and highly conserved processes governing cellular functions such as cell proliferation. After receiving his PhD at York University (Toronto), Dr. Johnston obtained his early training in yeast genetics with Dr. Leland H. Hartwell in the department of genetics at the University of Washington (Seattle). In 1975, Dr. Johnston was recruited to Dalhousie University. In 1992, Dr. Johnston was made a Terry Fox Cancer Research Scientist of the NCIC, and in 1995 he joined, and subsequently chaired, the Advisory Committee on Research (ACOR) of the NCIC, the senior committee of the NCIC that oversees all of the NCIC funding programs. In 2004 – 2006 served as president of the NCIC. From 2001 – 2006 Dr. Johnston also served as a member of the Institute Advisory for the CIHR Institute of Cancer Research. From 2004 – 2014 served as the CIHR University Delegate for Dalhousie. In August 2011, Dr. Johnston was inducted as a Fellow of the Canadian Academy of Health Sciences. Dr. Johnston currently chairs the Steering Committee on Research Excellence (SCORE) for the Terry Fox Cancer Research Institute which oversees the national program of team grants supported by the Terry Fox Foundation. Dr. Johnston also has served on and now chair’s the Interdisciplinary Adjudication Committee for the Canada Research Chair Program.
PLENARY 3: Friday, May 8 (continued)

Speakers

Sam Aparicio

Dr. Samuel Aparicio (BM, BCh, PhD, FRCPath) is the Nan & Lorraine Robertson Chair in Breast Cancer Research. He is also head of the BCCA's department of breast and molecular oncology, and a professor in the department of pathology and laboratory medicine at UBC. Dr. Aparicio graduated in medical and natural sciences from Cambridge University (UK), clinical medicine from Oxford, and subsequently in internal medicine and pathology. After doctoral work with Sydney Brenner in Cambridge he held a Wellcome Trust Career Development Fellowship at the Wellcome/CRUK Developmental Biology Institute. From 2000 to 2005 he was a senior investigator in the department of oncology, Cambridge. He was a co-leader of the international consortium that sequenced the genome of the pufferfish *Fugu rubripes* in 2002. He moved to Vancouver in 2005. Dr. Aparicio's research program encompasses the fields of cancer genomics, mouse genetic models, high-throughput screens, and translational breast cancer research. His most recent work on the molecular taxonomy of breast cancer led to identification of new genes that could change the way breast cancer is diagnosed, and form the basis of next-generation treatments. This discovery was preceded by another breakthrough in decoding the genetic makeup of the most-deadly form of breast cancer, known as triple negative subtype.

David Huntsman

Dr. David Huntsman (MD, FRCP, FCCMG) is a professor in the departments of pathology and laboratory medicine and obstetrics and gynaecology at the University of British Columbia (UBC) and is the Dr. Chew Wei Memorial Professor of Gynaecologic Oncology. He is a consulting pathologist at the Vancouver General Hospital (VGH). Dr. Huntsman is currently the director of the BC multidisciplinary ovarian cancer research team (OvCaRe), co-director of the Genetic Pathology Evaluation Centre (GPEC) at the Jack Bell Research Centre, VGH. His research has led to development of predictive and prognostic tissue-based cancer biomarkers for ovarian cancer and a wide variety of other tumour types. His team created a blueprint for subtype-specific ovarian cancer control and have been leaders in the application of novel genomics technologies to ovarian cancer. As collaboration is critical in his field, Dr. Huntsman happily leads and engages in a wide number of multidisciplinary research groups. Most recently he has been working on the creation of broad-based personalized medicine initiative for British Columbia.

David Malkin

Dr. Malkin is professor of pediatrics and medical biophysics at Pediatric Oncology Group of Ontario (POGO), chair in cancer control at the University of Toronto, and medical director of POGO. He is a pediatric oncologist and director of the cancer genetics program at SickKids, and senior scientist in the genetics and genome biology program. Dr. Malkin has published over 170 articles. His laboratory focuses primarily on the genetic and genomic mechanisms of childhood cancer susceptibility. His recent work explores the application of this genetic/genomic information to develop rational early detection and treatment approaches for children at genetic ‘high risk’ for cancer. He is funded by the CCS, CIHR, CFI, Genome Canada, the National Institutes of Health, Ewing Foundation Canada, and the US Department of Defense. In addition to giving over 200 invited lectures, and being recognized for his work in cancer research, clinical care and advocacy, Dr. Malkin has served on many national and international research grant panels, is past chair of the Advisory Council on Research for the CCSRI, and a member of the national board of directors of CCS.
Speakers (continued)

Marco Marro

Dr. Marra is the UBC Canada Research Chair in Genome Science and a member of the Order of British Columbia. He is a recipient of a 2013 UBC Killam Research Prize, a 2012 UBC Faculty of Medicine Distinguished Achievement Award, and the Medal of Merit Award from the International Association of Lions Club. He was elected to the Canadian Academy of Health Sciences in 2009; received the Frontiers in Research Award from the BC Innovation Council in 2008; and was appointed a Fellow of the Royal Society of Canada in 2007. He was a recipient of a Genome BC Award for Scientific Excellence, a MSFHR Career Investigator Senior Scholar Award, and Simon Fraser University President’s 40th Anniversary Award. In 2004, he received a Terry Fox Young Investigator Award and BC Biotech’s Innovation and Achievement Award (together with the entire GSC staff) for sequencing the SARS coronavirus genome. Dr. Marra was listed in the 2014 World’s Most Influential Scientific Minds by Thomson Reuters. He holds an honorary Doctor of Science degree from Simon Fraser University (2004) and an honorary Doctor of Laws degree from the University of Calgary (2005).
PLENARY 4: Saturday, May 9

Co-chairs

Michael Johnston
Dr. Johnston is a thoracic surgical oncologist and professor of surgery at Dalhousie University in Halifax, Nova Scotia. He received his MD degree from the University of Illinois, trained in general surgery at the University of Washington, and cardiothoracic surgery at the University of Pennsylvania. He held appointments as senior investigator in the surgery branch of the US National Cancer Institute and as head of surgical oncology at the University of Colorado Cancer Center before moving to Toronto in 1991. He practiced for many years at the Princess Margaret, Mt. Sinai and Toronto General hospitals and was professor of surgery at the University of Toronto. He and his co-investigators are currently in the process of commercializing a lymphatic targeting device through a joint venture in Wuxi, China. Dr. Johnston is director of the Beatrice Hunter Cancer Research Institute and TFRI’s Atlantic Region Node Leader.

Victor Ling
Dr. Victor Ling is the founding President and Scientific Director of the Terry Fox Research Institute. He is a professor of pathology and laboratory medicine at the University of British Columbia and a Distinguished Scientist at the BC Cancer Agency. He served previously as vice-president of research at the BC Cancer Agency and assistant dean at UBC. In that capacity he was instrumental in launching the Michael Smith Genome Sciences Centre in Vancouver and the construction of the $90-million BC Cancer Research Centre. Dr. Ling is known for his discovery of P-glycoprotein (MDR) and the superfamily of ABC transporters. He has been honoured by the General Motors Kettering Prize, the Gairdner Foundation International Award, a Michael Smith Foundation Distinguished Scholar Award and many others. He has received honorary degrees from four different Canadian universities, the Order of Canada, the Order of British Columbia, and is a Fellow of the Royal Society of Canada.

Speakers

Morag Park
Dr. Morag Park is a professor in the departments of oncology and biochemistry and joined McGill in 1989. She is a Fellow of the Royal Society of Canada, James McGill Professor and holds the Diane and Sal Guerrera Chair in Cancer Genetics at McGill University. Dr. Park received a B.Sc. with first-class honours from the University of Glasgow her PhD in viral carcinogenesis at the Medical Research Council Virology Institute in Scotland and completed postdoctoral training at the National Institutes for Cancer Research in Washington, DC. She joined McGill University in 1988. She was the director of the Molecular Oncology Group at the McGill University Hospital Centre (2006-8), scientific director of the Institute of Cancer Research for the CIHR (2008-13), co-chair of the Canadian Cancer Research Alliance (2008-2010) and is now director of the Goodman Cancer Research Centre (2013-present). Dr. Park is a research leader in the field of receptor tyrosine kinases (RTK) and mechanisms of oncogenic activation of RTKs in human cancers. She has recently developed leadership in the breast cancer microenvironment. She is the elected chair of the Tumour Microenvironment Network of the American Association for Cancer Research (2015-2017). She has more than 170 publications.

Tony Fields
Dr. Tony Fields, professor emeritus, department of oncology, University of Alberta, is a medical oncologist and a member of the medical staff of Alberta Health Services. Before retiring from full-time professional activities, he served in senior administrative roles within Alberta Health Services and the former Alberta Cancer Board. Dr. Fields is chair of the Health Quality Council of Alberta. He is also chair of the Provincial Advisory Council – Cancer of Alberta Health Services. On the inter-provincial scene, he is chair of the Expert Review Committee of the pan-Canadian Oncology Drug Review. He has been active in the NCIC Clinical Trials Group for many years and is a current member of the group’s Clinical Trials Committee. Dr. Fields has been recognized for his work by several awards, including an honorary doctorate of Athabasca University, the Distinguished Alumni Award of the University of Alberta, and the R.M. Taylor Medal and Award of the Canadian Cancer Society and the National Cancer Institute of Canada. In Alberta’s centennial year 2005 he was named one of Alberta’s 100 Physicians of the Century. In 2012, he was appointed a Member of the Order of Canada.
Speakers (continued)

Gerry Johnston
See page 7.

Catherine O’Brien
Dr. Catherine O’Brien, MD, is a surgical oncologist specializing in gastrointestinal malignancies at the University Health Network in Toronto, Ontario, and a scientist with the Ontario Cancer Institute. She is an assistant professor of surgery at the University of Toronto and holds a cross-appointment in the department of physiology as a faculty member. The focus of her research program is to develop a better understanding of the molecular pathways underlying the initiation and maintenance of colorectal cancers. She is interested in identifying the molecular pathways responsible for driving tumour growth in the subset of CRC cells enriched for tumour-initiating capacity, also referred to as colorectal cancer-initiating cells (CC-ICs). She holds research investigator awards from CIHR and the Terry Fox Research Institute. Dr. O’Brien holds a B.Sc. in physiology from McGill University, an MD from Queen’s University, an MA in physiology from Western University and a PhD in biomedical science from the University of Toronto.

Christine Williams
Dr. Williams was awarded a PhD in immunology from the University of Toronto, where she studied DNA repair pathways. She received additional postdoctoral training on the molecular biology of blood cell development and cancer at Massachusetts General Hospital and became an Instructor at Harvard Medical School. She returned to Toronto in 2005 as assistant director of research at the National Cancer Institute of Canada (NCIC) and director of the Canadian Prostate Cancer Research Initiative (CPCRI). In February 2009, the Canadian Cancer Society and the NCIC formally integrated operations to become a single organization and, shortly thereafter, Dr. Williams became the inaugural director of research for the new Canadian Cancer Society Research Institute. In January 2012, she was promoted to national vice-president, research responsible for overall leadership of research programs and initiatives at CCS. In July 2015, her portfolio was expanded to include leadership in advocacy and policy for the society as vice-president, research and policy.
Workshop 1

Judith Bray

Dr. Judith Bray completed her post-secondary education in England, obtaining a B.Sc. in biology from London University, a M.Sc. in immunology from the University of Birmingham, and a PhD in cancer immunology from the Cancer Research Campaign Laboratory, Nottingham. Following a two-year postdoctoral position, Judith moved to Canada to accept a position at the Cross Cancer Institute in Edmonton, Alberta. After a successful career as an independent investigator in cancer research for over six years, she took a leave from the workforce to raise her three sons. Judith then changed direction, joining the Canada Science and Technology Museum in Ottawa (CSTM) as an education officer, creating and delivering educational school science programs for CSTM as well as the Canadian Museum of Nature and the Department of National Defense. Judith joined CIHR in November 2000 to manage the launch of three institutes: the Institutes of Genetics, Cancer Research, and Infection and Immunity. Judith remained the assistant director of the Institute of Infection and Immunity and the Institute of Cancer Research for 14 years, working extensively on partnership development with organizations from both the public and private sector. In February 2014, Judith left CIHR, and retired from the federal government, to pursue opportunities as an independent consultant.

David Parkinson

David R. Parkinson, MD, is a venture partner at New Enterprise Associates (NEA). He previously was president and CEO of Nodality (2007-2012), a biotech company based in San Francisco. Until October 2007, Dr. Parkinson was senior-vice president, oncology research and development, at Biogen Idec where he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he was vice-president, oncology development, at Amgen and vice-president, global clinical oncology development, at Novartis. During his tenures at Amgen and Novartis, Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec, Femara, Zometa, Kepivance, and Vectibix. Dr. Parkinson worked at the National Cancer Institute (1990-1997), serving as chief of the investigational drug branch, then as acting associate director of the Cancer Therapy Evaluation Program. He is a past chair of the Food & Drug Administration (FDA) Biologics Advisory Committee. He has served on the National Cancer Policy Forum of the Institute of Medicine, and as a board director of the Ontario Institute for Cancer Research. Dr. Parkinson received his medical degree from the University of Toronto. He has held academic positions both at Tufts and at the University of Texas MD Anderson Cancer Center.

Workshop 2

Brad Nelson

Dr. Nelson is a native of Vancouver, BC. He received a B.Sc. from the University of British Columbia in 1987 and a PhD from the University of California at Berkeley in 1991. He completed postdoctoral training and held faculty positions at the Fred Hutchinson Cancer Research Center and University of Washington in Seattle, before moving his lab to the Benaroya Research Institute in Seattle in 1997. In July 2003, he became the founding director of the BC Cancer Agency’s Deleeley Research Centre in Victoria, BC. He is a professor of medical genetics at the University of British Columbia and a professor of biochemistry/microbiology at the University of Victoria. Dr. Nelson’s lab studies the immune response to cancer, with an emphasis on ovarian, breast and lymphoid cancers. His team is developing a Phase I clinical trials program focused on T cell-based immunotherapies for cancer.
Workshop 2 (continued)

Pam Ohashi

Dr. Ohashi received her PhD from the University of Toronto with Dr. Tak Mak, and did her post-doctoral training at the University of Zurich with the Nobel Laureate Dr. Zinkernagel, and Dr. Hans Hengartner. She is the co-director of the Campbell Family Institute for Breast Cancer Research, senior scientist at the Princess Margaret Cancer Centre, and professor in the departments of medical biophysics and immunology at the University of Toronto. She is also the director of the Immune Therapy Program at the Ontario Cancer Institute/Princess Margaret Cancer Centre. Her interests are understanding T cell tolerance, strategies to promote tissue-specific immune responses and translating these findings to clinical trials.

Workshop 3

Stephen Lam

Stephen Lam, MD, FRCPC, is professor of medicine at the University of British Columbia and a distinguished scientist at the BC Cancer Research Center. He chairs the Provincial Lung Tumour Group at the BC Cancer Agency. He directs the MDS-Rix Early Lung Cancer Detection and Translational Research Program at the BCCA. His research interest is in early detection, chemoprevention and endoscopic therapy of lung cancer. He is co-PI of the Terry Fox Research Institute Pan-Canadian Early Detection of Lung Cancer Study. He was the recipient of the Joseph Cullen Award for lifetime scientific achievements in lung cancer prevention research by the International Association for the Study of Lung Cancer. Dr. Lam received his medical training at the University of Toronto and did his residency and fellowship training in internal medicine and pulmonary medicine at University of British Columbia-associated hospitals. He joined the UBC Faculty of Medicine in 1979 and the BC Cancer Agency in 1984.

Louise Parker

Dr. Louise Parker is a cancer epidemiologist who was appointed as the Canadian Cancer Society (Nova Scotia division) Chair in Population Cancer Research at Dalhousie University in Halifax in 2007. She has extensive expertise in leading etiological research – especially in childhood cancer and adult disease – and has received extensive national and international funding for her research, which has included the study of transgenerational effects of radiation exposure and childhood cancer, screening for neuroblastoma and life-course influences on adult onset disease and continuous traits. Her expertise in health effects of radiation led to her being appointed to the UK government advisory committees on the medical aspects of radiation in the environment. She is currently principal investigator of the Atlantic PATH project, which is part of the CPAC-funded Canadian Partnership for Tomorrow Project, the largest prospective cohort study ever undertaken in Canada. Atlantic PATH, the largest population cohort study undertaken in Atlantic Canada, has recruited over 30,000 men and women, from all four Atlantic provinces with biological specimens, physical measures and information. She has just completed her term as chair of the CIHR Cancer Research Institute Advisory Board and sits on research committees of the Public Health Agency of Canada, Health Canada and the Canadian Cancer Society.
Workshop 4

Catherine O’Brien

See page 11.

Francis Rodier

Dr. Francis Rodier is an assistant professor in the radiology, radio-oncology and nuclear medicine department in the Faculty of Medicine, Université de Montréal (UdeM). He holds an FRQS Junior I Career Award and is a Terry Fox New Investigator. His laboratory is established at the Centre hospitalier de Université de Montréal and his expertise focuses on the roles of mammalian DNA damage signalling pathways and cellular senescence during cancer progression and treatment. Dr. Rodier earned his PhD in molecular biology at UdeM where he used transgenic mouse models expressing viral oncoproteins to uncover genetic or epigenetic events involved in cancer progression. He subsequently performed his postdoctoral research at the Lawrence Berkeley National Laboratory (University of California-Berkeley) and Buck Institute for Age Research in California with cellular senescence expert Judith Campisi, which allowed him to develop his complementary interests in cancer and aging.

Workshop 5

John Bell

Dr. John Bell received his PhD from McMaster University in 1982. The three years that followed, he trained as a postdoctoral fellow at the University of Ottawa and then at the Medical Research Council in London, England. Dr. Bell began his independent research career at McGill University in 1986 and moved to the University of Ottawa, department of medicine, in 1989. He is a member of the Center for Cancer Therapeutics at The Ottawa Hospital Cancer Center, a senior scientist with the Ottawa Hospital Research Institute and a professor of medicine at the University of Ottawa. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox-funded group from across Canada that is developing virus-based cancer therapeutics and is the director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. He is the scientific director of the recently awarded National Centre for Excellence for the development of Biotherapeutics for Cancer Therapy.

Bradly G. Wouters

Dr. Bradly G. Wouters is currently senior scientist and director of the Hypoxia and Microenvironment Program at the Princess Margaret Cancer Centre in Toronto and a full professor in the departments of radiation oncology and medical biophysics at the University of Toronto. He has recently assumed the position of interim director of research at the Princess Margaret Cancer Centre. He is cross appointed as an associate chair of graduate studies and director of radiation biology within the department of radiation oncology as well as senior investigator in the Selective Therapy Program at the Ontario Institute for Cancer Research. He has been a faculty member on the European Society for Radiotherapy and Oncology (ESTRO) teaching course on Basic Clinical Radiobiology in Europe for the past 10 years and was also the director of the ESTRO Molecular Oncology for the Radiation Oncologist course for more than five years. He has contributed as an author to several of the chapters in the Basic Clinical Radiobiology textbook used in Europe and many other parts of the world. He is an internationally recognized leader in the field of molecular radiation oncology with a primary interest in understanding the cellular and molecular responses to hypoxia and their influence on the biological behavior of tumours.
Workshop 6

Janet Dancey
Dr. Dancey is director, NCIC Clinical Trials Group and scientific director, Canadian Cancer Clinical Trials Network and professor, department of oncology, Queen’s University. Previously, she was program director for High-Impact Clinical Trials, Ontario Institute for Cancer Research (OICR), director, Clinical Translational Research. She completed medical school at the University of Ottawa in 1988. She received certifications in internal medicine and medical oncology from the Royal College of Physicians and Surgeons of Canada in 1992 and 1993. She has completed research fellowships at the NCIC Clinical Trials Group (NCIC CTG) and at the Institut Gustave Roussy, Villejuif, France. In 1999, she became senior investigator in the Investigational Drug Branch of the Cancer Therapy Evaluation Program of the National Cancer Institute and rose to associate chief prior to returning to Canada. In her current position, Dr. Dancey is responsible for leading Canada’s largest adult cancer clinical trial co-operative group and developing the Canadian Cancer Research Alliance-supported Clinical Trial Program. Her clinical focus is on melanoma and gastrointestinal malignancies. Her research interests include novel trials to evaluate investigational drugs in rare tumour settings, to evaluate next-generation sequencing technologies in cancer patient management and trial methodology.

Lillian Siu
Dr. Lillian Siu is a senior staff medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a professor of medicine at the University of Toronto since 2009. Dr. Siu is the director of the Phase I Program at the Princess Margaret Cancer Centre. She currently serves on the board of directors for the American Society of Clinical Oncology (ASCO) (2012-2016). She also serves as a member of the Nomination Committee for the American Association for Cancer Research (AACR) (2014-2016). Her major research focus is in the area of new anti-cancer drug development, particularly with respect to Phase I trials and head and neck malignancies. She is the principal investigator of a Phase I co-operative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition, Dr. Siu has been leading genomics initiatives in the area of precision medicine at the Princess Margaret Cancer Centre. Internationally, she was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010. She has published over 170 peer-reviewed manuscripts, and is currently a scientific editor for Cancer Discovery and is on the editorial boards for the Journal of Clinical Oncology, Cold Spring Harbor Molecular Case Studies and JAMA Oncology.
Chair

**Anne-Marie Mes-Masson**

Dr. Anne-Marie Mes-Masson is a professor in the department of medicine at the Université de Montréal. She is presently the scientific director of the Institut du cancer de Montréal and head of cancer research at the Centre de recherche du Centre Hospitalier de l’université de Montréal (CRCHUM). In 2003, Dr. Mes-Masson was named the director of the Réseau de recherche sur le cancer du Fonds de recherche Québec - Santé (FRQS). Her research includes the development of cancer models and the identification of molecular events that contribute to cancer development, and her research has focused mainly on ovarian and prostate cancer. Dr. Mes-Masson has developed multiple collaborations and participates in several translational oncology research initiatives.
The Terry Fox Research Institute
from coast to coast

TFRI is an Institute without walls linking the capabilities of 64 leading cancer care and cancer research institutes and universities organized through six regional “nodes”.

NATIONAL PARTNERS
The Terry Fox Foundation
Canadian Partnership Against Cancer Corporation (CPAC)
Canadian Tumour Repository Network (CTRnet)
Genome Canada

BRITISH COLUMBIA
BC Cancer Agency
BC Cancer Foundation
The Centre for Drug Research and Development
Genome British Columbia
St. Paul’s Hospital (Providence Health)
Simon Fraser University
Team Finn Foundation
University of British Columbia
Vancouver Coastal Health Research Institute

ALBERTA
Alberta Cancer Foundation
Alberta Health Services
Alberta Innovates – Health Solutions
Cross Cancer Institute
Genome Alberta
Tom Baker Cancer Centre
University of Alberta
University of Calgary

PRAIRIES
CancerCare Manitoba
Manitoba Health Research Council
Saskatchewan Cancer Agency
Saskatchewan Health Research Foundation
University of Manitoba
University of Saskatchewan

ONTARIO
Brock University
Children’s Hospital of Eastern Ontario
Hospital for Sick Children
Juravinski Cancer Centre
London Health Sciences Centre
McMaster University
Mount Sinai Hospital
Ontario Cancer Institute
Ontario Institute for Cancer Research
Ottawa Hospital Research Institute
Queen’s University
Sunnybrook Research Institute
Thunder Bay Research Institute
University Health Network (Princess Margaret Cancer Centre)
University of Ottawa
University of Toronto

QUEBEC
Centre hospitalier de L’Université de Montréal
Centre hospitalier Universitaire du Québec
Hôpital Maisonneuve-Rosemont
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Jewish General Hospital
L’Institut de Recherches Cliniques de Montréal
McGill Cancer Centre
McGill University Health Centre
McGill University
Université de Montréal
Université Laval
Université Sherbrooke

ATLANTIC
Atlantic Cancer Research Institute (Moncton)
Capital District Health Authority
Dalhousie University (Halifax)
New Brunswick Health Research Foundation
Memorial University of Newfoundland (St John’s)
New Brunswick Cancer Network
QEI Health Sciences Centre (Halifax)
The University of New Brunswick
The University of Prince Edward Island